Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update

Core Insights - Rakovina Therapeutics Inc. reported its financial results for Q4 and the fiscal year ending December 31, 2024, highlighting advancements in AI-powered drug discovery for cancer therapies [1][2] Financial Performance - The company had a net loss of $1,483,988 for Q4 2024 and $4,072,618 for the entire year [4] - Research and development expenses were $744,533 for Q4 and $2,341,600 for the year, while general and administrative expenses were $650,268 for Q4 and $1,446,451 for the year [4][5] - As of December 31, 2024, the company had cash and cash equivalents of $1,312,743 and total assets of $6,240,920, with total liabilities of $1,942,005 [5] Corporate Developments - The company intends to appoint Yevgeniy Meshcherekov and David Kideckel to its board of directors, pending TSX Venture Exchange approval [2] - Michael Liggett has retired from the board, and Meshcherekov is set to replace him as chair of the audit committee [2] - Rakovina presented pre-clinical data for its kt-2000 and kt-5000 programs at the AACR annual meeting, indicating potential alignment with target product profiles [2] Research and Development - The company received its first synthesized batch of AI-generated ATR inhibitor compounds in collaboration with Variational AI [2] - Rakovina has established a pipeline of DNA-damage response inhibitors and aims to advance drug candidates into human clinical trials [6][7] - Collaborations with UBC and Pharma Inventor Inc. have been expanded to support AI drug discovery initiatives [8]